Alcon Posted In-Line Third-Quarter Sales and Tightened Its 2026 Guidance

Alcon reported third-quarter net sales of $2.72 billion on Tuesday, up 4.9 percent from $2.59 billion a year earlier.

The Geneva-based eye-care company released results for the three months ended September 30, 2026, after the New York close.

Core diluted earnings per share were $0.91, two cents ahead of the $0.89 consensus published by Zacks, while the $2.72 billion in net sales sat just under the $2.73 billion Zacks had forecast.

Core earnings strip out amortization and one-time items to show underlying performance, and consensus is tracked on that basis; the reported figures below follow IFRS, the international accounting rules.

Core diluted earnings per share a year earlier were $0.79, so the quarter's core profit per share rose 15.2 percent year over year.

Chief Executive David J. Endicott said: "We remain on track for our 2026 objectives with year-to-date sales growth of six percent and double-digit core EPS growth, despite some specific areas of competitive pressure."

Surgical grew 4 percent as Vision Care rose 6 percent

Surgical, the larger of Alcon's two divisions, contributed $1.48 billion of net sales, up 4 percent from $1.42 billion a year earlier.

Implantables, which covers intraocular lenses used in cataract surgery, fell 2 percent to $422 million from $432 million.

Intraocular lens sales fell 1 percent in constant currency on U.S. competitive pressure, partly offset by PanOptix Pro and international growth.

Consumables used in eye operations rose 6 percent to $789 million from $745 million.

Equipment and other sales climbed 11 percent to $269 million from $243 million, led by launches including the Unity platform and Valeda.

Vision Care net sales rose 6 percent to $1.24 billion from $1.17 billion, with contact lenses up 4 percent to $737 million from $707 million.

Contact lenses rose 5 percent in constant currency, and ocular health, which includes eye drops and lens-care products, rose 8 percent to $500 million from $462 million.

Ocular health growth was led by Tryptyr and Systane, and other revenues contributed a further $20 million, taking total revenue to $2.74 billion.

Core operating income rose 13 percent as reported profit climbed

On a reported basis, operating income rose to $381 million from $332 million, and net income increased to $260 million from $237 million, lifting diluted earnings per share to $0.54 from $0.48.

Reported operating margin was 14.0 percent, up from 12.8 percent.

Core operating income rose 13 percent to $591 million from $523 million, and core margin widened to 21.8 percent from 20.2 percent.

Third-quarter operating income included tariff refunds of $58 million, alongside lower amortization and manufacturing efficiencies.

Guidance tightened, with the margin range added

For the full year, Alcon narrowed its guidance on a constant-currency basis, which strips out exchange-rate movements, and now expects net sales growth of about 6 percent.

That tightens the 5 to 7 percent range set in August; the company labeled the change Tightened.

Core operating margin is now expected to improve by 100 to 150 basis points, a tightened range from the 90 to 190 basis points guided in August.

A basis point is one hundredth of a percentage point.

Growth in core diluted earnings per share is now guided at 12 to 14 percent for 2026, narrowed from the 12 to 15 percent range in the August outlook.

The tighter ranges keep Alcon's year on plan rather than lifting it: about 6 percent sits inside the old band, not above it, and the earnings band lost its top end.

Cash flow, buybacks and the tariff and efficiency updates

For the first nine months, net cash from operating activities was $1.69 billion, up from $1.61 billion, and free cash flow was $1.35 billion, up from $1.24 billion.

Alcon returned $210 million in the third quarter through share repurchases, and $748 million year to date through dividends and buybacks.

About $1.0 billion remained at September 30 of the $1.5 billion repurchase authorization.

The outlook assumes a full-year tariff impact of about $40 million, net of mitigation and refunds, reflecting the approximately $60 million refund received in the third quarter.

About two-thirds of the refund benefit is being reinvested in the business.

In November, Alcon expanded its February efficiency measures, lifting total estimated costs to about $230 million.

Estimated run-rate savings rose from about $100 million to about $130 million, to help offset inflation, with implementation still expected to complete in 2026.

A second-quarter charge still weighs on nine-month profit

Reported diluted earnings per share for the nine months were $0.92, down 40 percent from a year earlier, while core diluted earnings per share rose 14 percent to $2.60.

The nine-month drop mainly reflects a post-tax, non-cash net charge of about $287 million for discontinuing the PowerVision programs, plus efficiency-measure costs.

The charge began with a $402 million pre-tax, non-cash charge in the second quarter to discontinue intraocular lens programs acquired from PowerVision.

First-half reported earnings per share were $0.39, against core earnings per share of $1.69.

Nine-month net sales were $8.18 billion; the prior year also included $142 million of gains on fair-value remeasurements of investments in associated companies.

Alcon completed its $550 million acquisition of Neurotech Pharmaceuticals in October, adding the ENCELTO retinal implant, a deal TickerGrove covered when it was announced on October 20.

Shares fell in after-hours trading after a strong run into the print

Alcon shares closed at $74.06 in New York on Tuesday, down 1.44 percent from $75.14, before the results were released.

In after-hours trading, the shares fell about 5.5 percent by 7:59 PM Eastern on Tuesday, with StockAnalysis at $70.00 and MarketBeat at $69.98.

The shares had risen about 16.8 percent over the past month into the print, by Zacks' tally.

The earnings call and the fourth quarter are next

What to watch: management discusses the quarter on a call at 8:00 AM Eastern on Wednesday, and investors will test whether the tighter guidance leaves room for a strong fourth quarter.

What remains unknown

No standalone fourth-quarter guidance was given, so the full-year ranges imply the closing quarter's pace without pinning it down, and management has not yet commented beyond the release.

How much Neurotech contributes is still open: October coverage put it as slightly dilutive to core diluted earnings per share in 2027, accretive thereafter.